Efterhånden er ganske mange studier på Clinical Trials opdateret til at have fuldt optag (aktive, men ikke længere rekrutterende):
-
Efterhånden er ganske mange studier på Clinical Trials opdateret til at have fuldt optag (aktive, men ikke længere rekrutterende):
Active, not recruiting Ofatumumab Dose-finding in RRMS Patients
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: ofatumumab/placebo
Phases: Phase I / Phase II
Last Updated Date: May 20, 2010
Primary Completion Date: September 2010Active, not recruiting Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL), Untreated
Interventions: Drug: chlorambucil, tablets; Drug: ofatumumab (GSK1841157) infusion
Phase: Phase III
Last Updated Date: August 25, 2011
Primary Completion Date: March 2013Active, not recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia; Waldenstrom Macroglobulinaemia
Intervention: Biological: Ofatumumab
Phase: Phase II
Last Updated Date: August 11, 2011
Primary Completion Date: March 2013Active, not recruiting Ofatumumab Retreatment and Maintenance Treatment in CLL Patients
Condition: B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
Phase: Phase II
Last Updated Date: July 21, 2011
Primary Completion Date: February 2012Active, not recruiting Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Lenalidomide; Drug: Ofatumumab
Phase: Phase II
Last Updated Date: July 14, 2011
Primary Completion Date: November 2013Active, not recruiting A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Drug: ofatumumab 100 mg, 1000 mg / vial
Phase: Phase II
Last Updated Date: April 21, 2011
Primary Completion Date: June 2011Active, not recruiting Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Condition: Non-Hodgkin's Lymphoma (NHL)
Intervention: Drug: Bendamustine and Ofatumumab
Phase: Phase II
Last Updated Date: April 15, 2011
Primary Completion Date: July 2011Active, not recruiting Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
Condition: Diffuse Large B Cell Lymphoma (DLBCL)
Intervention: Drug: Ofatumumab
Phase: Phase II
Last Updated Date: July 7, 2011
Primary Completion Date: May 2010
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind